Artikel
Detection of SARS-CoV2-specific antibody-releasing plasma cells using fluorospot technology in patients after mRNA vaccination
Suche in Medline nach
Autoren
-
Lena Vullriede
- University Medical Center Schleswig-Holstein, Campus Kiel, Medical Department 1, Department for Rheumatology and Clinical Immunology, Kiel
-
Ulf Geisen
- University Medical Center Schleswig-Holstein, Campus Kiel, Medical Department 1, Department for Rheumatology and Clinical Immunology, Kiel
-
Maria Ciripoi
- University Medical Center Schleswig-Holstein, Campus Kiel, Medical Department 1, Department for Rheumatology and Clinical Immunology, Kiel
-
Hayley Marie Reid
- University Medical Center Schleswig-Holstein, Campus Kiel, Medical Department 1, Department for Rheumatology and Clinical Immunology, Kiel
-
Dennis Berner
- University Medical Center Schleswig-Holstein, Campus Kiel, Medical Department 1, Department for Rheumatology and Clinical Immunology, Kiel
-
Florian Tran
- University Medical Center Schleswig-Holstein, Campus Kiel, Department for Internal Medicine 1, Kiel; Christian-Albrechts-Universität zu Kiel, Institute for Clinical Molecular Biology, Kiel
-
Melike Sümbül
- University Medical Center Schleswig-Holstein, Campus Kiel, Department for Dermatology, Kiel
-
Annika Schaffarzyk
- University Medical Center Schleswig-Holstein, Campus Kiel, Department for Rheumatology and Clinical Immunology, Kiel
-
Jan Schirmer
- University Medical Center Schleswig-Holstein, Campus Kiel, Medical Department 1, Department for Rheumatology and Clinical Immunology, Kiel
-
Rainald Zeuner
- University Medical Center Schleswig-Holstein, Campus Kiel, Medical Department 1, Department for Rheumatology and Clinical Immunology, Kiel
-
Anette Friedrichs
- University Medical Center Schleswig-Holstein, Campus Kiel, Department for Internal Medicine 1, Kiel
-
Andrea Steinbach
- University Medical Center Schleswig-Holstein, Campus Kiel, Medical Department 1, Department for Rheumatology and Clinical Immunology, Kiel
-
Sascha Gerdes
- University Medical Center Schleswig-Holstein, Campus Kiel, Department for Dermatology, Kiel
-
Petra Bacher
- University Medical Center Schleswig-Holstein, Campus Kiel, Institute of Immunology, Kiel
-
Stefan Schreiber
- University Medical Center Schleswig-Holstein, Campus Kiel, Institute for Clinical Molecular Biology, Kiel
-
Bimba F. Hoyer
- University Medical Center Schleswig-Holstein, Campus Kiel, Medical Department 1, Department for Rheumatology and Clinical Immunology, Kiel
| Veröffentlicht: | 14. September 2021 |
|---|
Gliederung
Text
Introduction: mRNA vaccinations are a new technology introduced in the context of the current SARS-CoV2 pandemic. As the immune response to SARS-CoV2 is not fully understood, tools to measure the specific immune response are urgently needed. Elispot technology is able to demonstrate the functionality of plasma cells and plasmablasts to secret antibodies of a certain specificity. Fluorospot multicolour technology allows to detect multiple istoytpes in parallel and therefore minimized sample errors and sample size. We here present for the first time data on the antigen-specific detection of SARS-CoV2 spike protein specific plasmablasts and plasma cells using multicolour fluorescent Elispot.
Methods: 28 healthy donors and 25 patients with pre-existing chronic inflammatory diseases under anti-cytokine therapy were included. All donors were immunized with mRNA vaccines against SARS-CoV2 as part of the german vaccination campaign. Both groups received either BioNTech/Pfizer or Moderna vaccine 21-35 days after the first dose. Peripheral Blood Mononuclear Cells (PBMC) were isolated from blood samples followed by a Fluorospot assay detecting total IgA/IgG/IgM or anti SARS-CoV-2 S1 spike protein antibodies of all three isotypes. Analysis was performed on day 0 before vaccination and on day 7 following the secondary vaccination.
Results: On day 0 prior to the first immunization no SARS-CoV2 specific plasma cells could be detected in patients or controls in the peripheral blood. However, on d7 after the secondary immunization SARS-CoV2 specific plasma cells could be detected in all samples and all isotypes.
Conclusion: In both cohorts the presence on SARS-CoV2-specific plasma cells after secondary immunization could be demonstrated using fluorospot technology. This is the first time, that the effective and specific detection of Anti-SARS-Cov2 antibody secreting cells could be demonstrated in a multicolour fluorescent ELISPOT after mRNA-vaccination to SARS-CoV2 in healthy donors but also in patients under anti-cytokine therapy. In a next step, differences between the immunoglobulin isotypes will be analysed in more detail, to understand the differences in the immune response between patients and controls.
Disclosures: Lena Vullriede: keine, Ulf Geisen: keine, Maria Ciripoi: keine, Hayley Marie: keine, Dennis Berner: keine, Florian Tran: keine, Melike Sümbül, Annika Schaffarzyk: keine, Jan Schirmer: keine, Rainald Zeuner: keine, Anette Friedrichs: keine, Andrea Steinbach: keine, Sascha Gerdes: keine, Petra Bacher: keine, Stefan Schreiber: Pfizer, Bimba Franziska Hoyer: Pfizer
